Literature DB >> 8186339

Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection.

J C Thijs1, A A Van Zwet, W Moolenaar, J A Oom, H De Korte, E A Runhaar.   

Abstract

BACKGROUND: Triple therapy for Helicobacter pylori using metronidazole is less effective in patients with a metronidazole resistant strain. Moreover, metronidazole is responsible for many side-effects. This open study examined the efficacy and side-effects of a triple treatment regimen substituting clarithromycin for metronidazole.
METHODS: 36 patients with a H. pylori infection, proven by culture, were treated with tripotassium dicitrato bismuthate 120 mg q.d.s., tetracycline 250 mg q.d.s. and clarithromycin 250 mg q.d.s. for 10 days. Eradication was defined as a negative culture and histological examination of antral biopsy specimens, taken at least 6 weeks after completion of the treatment.
RESULTS: Eradication was achieved in 26 patients (72%). The treatment was well tolerated with only 4 (11%) of the patients having significant side-effects.
CONCLUSION: Triple therapy with clarithromycin seems to be less effective than standard triple treatment when the prevalence of metronidazole resistance is low. It is suggested, however, that this combination could be a valuable alternative in areas with a high prevalence of metronidazole resistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186339     DOI: 10.1111/j.1365-2036.1994.tb00170.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

Review 1.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

2.  Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong.

Authors:  C K Ching; K P Leung; R W Yung; S K Lam; B C Wong; K C Lai; C L Lai
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

3.  Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands.

Authors:  A A van Zwet; W A de Boer; P M Schneeberger; J Weel; A R Jansz; J C Thijs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

4.  Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori.

Authors:  Salman R Hasan; Vahabzadeh Vahid; Pahlvanzadah M Reza; Salman R Roham
Journal:  Saudi J Gastroenterol       Date:  2010 Jan-Mar       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.